ORG 2766 fails to improve visual functions in rats with occipital lesions

Chronic administration of ORG 2766 for 6 months produces a subtle impairment in strategic learning by rats

Rats were administered saline or 10 micrograms of the ACTH4-9 analog ORG 2766 on alternate days for 160 days (i.e. 80 injections total). Behavioral assessments began 1 week later. Locomotor competence was assessed by examining the number of slips and falls made by the animals on a rotating rod. The rats were also trained on a position task and 10 subsequent position reversals in a 'T' shaped water maze. Exposure to ORG 2766 failed to affect either locomotor competence or the overall number of errors committed while learning the original position habit and 10 reversals. However, the response accuracy of the ORG 2766-treated animals on trial 2 of the reversals was equivalent to that expected by chance (58% correct choices), whereas saline-treated animals effectively altered their behavior after experiencing nonreinforcement on the initial trial of a reversal (77% correct choices). This result is consistent with other observations revealing that ORG 2766 can influence attention and, therefore, some cognitive functions.

The ACTH(4-9) analog ORG 2766 and recovery after brain damage in animal models--a review

Treatment with adrenocorticotrophic hormone (ACTH), as well as with ACTH fragments and analogues, can influence behaviour of animals and humans. Furthermore it facilitates recovery of damaged peripheral nervous tissue. The question whether ACTH/MSH peptides affect recovery processes after injury to the central nervous system as well is addressed in the present review. The effects of administration of the ACTH(4-9) analog ORG 2766 after brain lesions has been studied frequently. However, the interpretation of the available data is confused by the variability of the results. Several factors can be identified which influence the efficacy of the peptide: (i) not all behavioural tests are equally suitable to reveal a peptide effect on behavioural recovery; (ii) the affected brain area; (iii) whether cell bodies or terminals are affected; (iv) the post-operative housing conditions; and (v) the onset and duration of peptide administration. Two possible explanations of peptide efficacy on functional recovery are considered: first, the peptide may accelerate spontaneously occurring recovery processes and second, the peptide may induce compensatory mechanisms underlying functional recovery without recuperation of the damaged neurons. These compensatory mechanisms seem to rely mainly on enhanced non-selective attention by activation of limbic structures. It is as yet unknown to which receptor system ORG 2766 binds; the analog lacks affinity for the known melanocortin (MC) receptors in brain, yet ORG 2766 is able to modulate the activity of endogenous opioids and the NMDA-receptor. A modulating influence of the peptide on NMDA-receptor activity might indirectly account for both enhanced attention--with ensuing behavioural recovery--and the acceleration of spontaneous recovery.

The influences of fragments and analogs of ACTH/MSH upon recovery from nervous system injury

Post-injury treatment with some fragments and analogs of the adrenocorticotropic hormone (ACTH) can influence recovery after nervous system injury. This review considers both the successful and unsuccessful attempts to facilitate neural and behavioral recovery from nervous system damage via post-injury administration of these compounds. To date no single unifying explanation for the mixed results observed in animals prepared with forebrain injuries has been achieved. Several possible explanations for the variety of observations reported and several potentially productive avenues for future research are suggested.